Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL
Status:
Recruiting
Trial end date:
2021-12-11
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of CD19/CD22 Bispecific CAR-T for the treatment of
MRD-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning
chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of
CD19/CD22 CAR+ T cells.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine